Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 161

Results For "new"

5327 News Found

Experts highlight critical link between mental well-being and cardiovascular health
Healthcare | September 29, 2025

Experts highlight critical link between mental well-being and cardiovascular health

Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference


FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Drug Approval | September 29, 2025

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor


Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025
Digitisation | September 29, 2025

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies


AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease
Drug Approval | September 29, 2025

AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease

If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option


Amgen invests $650 million on expansion of US manufacturing network
News | September 29, 2025

Amgen invests $650 million on expansion of US manufacturing network

Amgen has invested over $40 billion in manufacturing and research and development in US since 2017


Enhertu improved in invasive disease-free survival in early breast cancer in DB-05
Clinical Trials | September 29, 2025

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting


AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs


Lilly opens biotech in San Diego
Startup | September 29, 2025

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines